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Objectives. To evaluate the characteristics of presentation, biochemical profile, and etiology of gynecomastia in adults. Methods.
Medical records of 237 men aged 18-85 years with gynecomastia were evaluated. Results. Highest prevalence of gynecomastia was
observed between 21 and 30 years (n = 74; 31.2%). The most common presenting complaints were aesthetic concerns (62.8%) and
breast pain (51.2%). 25.3% of the subjects had a history of pubertal gynecomastia. 56.5% had bilateral gynecomastia. 39.9% were
overweight and 22.8% were obese. The etiology could not be identified in 45.1% of the cases; the most frequent identified causes
were anabolic steroids consumption (13.9%), hypogonadism (11.1%), and use of pharmaceutical drugs (7.8%). Patients with bilateral
gynecomastia had a longer history of disease, higher BMI, and lower testosterone levels. Conclusions. Patients with gynecomastia
presented more often with aesthetic concerns and secondarily with breast pain. The most frequent final diagnosis was idiopathic
gynecomastia, whereas the most frequent identified etiologies were anabolic steroids consumption, hypogonadism, and use of
pharmaceutical drugs. Despite the low frequency of etiologies such as thyroid dysfunction or adrenal carcinoma, we emphasize the
importance of a thorough assessment of the patient, as gynecomastia may be the tip of the iceberg for the diagnosis of treatable
diseases.
1. Introduction
Gynecomastia, defined as the benign proliferation of breast
glands in males, is a common complaint that produces
anxiety and discomfort and it may be the expression of a
clinically relevant disease [1, 2].
Gynecomastia may be diagnosed on routine clinical
examination or patients may present with complaints of a
retroareolar nodule. This condition may occur sporadically
or in a familial setting, and it may be unilateral or bilateral,
painful or painless, of acute onset or progressive growth [3–
5].
The hormones involved in breast tissue physiology may
be stimulatory (as estradiol and progesterone) or inhibitory
(as testosterone), acting directly through their specific recep-
tors at this level [6, 7]. Receptors for insulin-like growth
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factor 1 (IGF-1), IGF-2 [8], luteinizing hormone, and human
chorionic gonadotropin have also been detected in breast
tissue [7, 8]. Estrogens and progesterone apparently require
the presence of growth hormone and IGF-1 to exert their
stimulatory action on the breast [9].Hyperprolactinemiamay
indirectly cause gynecomastia by suppressing gonadotropin-
releasing hormone (GnRH) release, resulting in central
hypogonadism, although prolactin receptors have also been
detected in benign and malignant breast tissue. At breast
level, prolactin might modulate progesterone and androgen
receptors expression (increasing the former and reducing the
latter) [10]. Furthermore, prolactin stimulates epithelial cell
proliferation only in the presence of estrogen and enhances
lobuloalveolar differentiation only with concomitant proges-
terone [7].
Gynecomastia may result from an excess of estrogens
(obesity, tumors, and exogenous sources) [11], androgen defi-
ciency (hypogonadism), hormone resistance [12], or altered
ratio of estrogens to androgens (refeeding, liver disease, and
renal failure) [13].
It may also be a physiological phenomenon in different
stages of life, such as in the newborn, during pubertal
development [14], and in the elderly [15, 16], or it may be
a pathological condition caused by drugs of abuse [17, 18],
systemic disease [17, 19], endocrine disorders, tumors, and
medications [17]. Even though gynecomastia is a common
condition, e.g., palpable breast tissue may be detected in one-
to two-thirds of adult males, while autopsy data suggest a
prevalence of 40-55% [19–23], the relative prevalence of the
various etiologies has only been investigated in a few series,
most of them with a low number of patients. Further studies
are required in a larger number of subjects to evaluate the
etiology and characteristics of this disease.
The aims of our study were to evaluate the etiology and
the clinical presentation of gynecomastia and the biochemical
profile in a group of adult men seeking specialized endocrine
care.
2. Material and Methods
All the medical records of males aged >18 years who pre-
sented with gynecomastia or were diagnosed with gyneco-
mastia when presenting with other complaints from May
2004 to June 2014 were evaluated in a cross-sectional, analyt-
ical, retrospective, multicenter study.The sites where patients
were seen are located in Buenos Aires and are attended by a
population with middle to high cultural and socioeconomic
status.
Inclusion criteria for medical records were as follows:
(i) Data on the following clinical factors: breast pain,
duration, presence of galactorrhea, habits (alcohol, drugs of
abuse, and anabolic drugs), history of pubertal gynecomastia,
medical history, and use of medication. The consumption of
marijuana and other drugs was self-reported.
(ii) Hormonal laboratory assessment: total testosterone
(TT), estradiol (E2), luteinizing hormone (LH), follicle-
stimulating hormone (FSH), prolactin (PRL), and thyroid-
stimulating hormone (TSH).
(iii) Imaging confirming diagnosis (mammography
and/or ultrasound).
In all patients, gynecomastia was confirmed by ultra-
sound and/or mammography.
The following data were collected from physical exam-
ination: weight and height; body mass index (BMI) was
calculated using the formula: weight (kg)/height (m)2. A
BMI 18.5-25 kg/m2 was considered normal weight, a BMI
≥25 and <30 kg/m2 was considered overweight and a BMI
≥30 kg/m2 was considered obese. A breast examination was
performed: the patient lies flat on his back with his hands
clasped beneath his head. Using the separated thumb and
forefinger, the examiner slowly brings the fingers together
from either side of the breast. True glandular breast tissue
(gynecomastia) can be distinguished from fatty breasts by
comparing subareolar tissue with adjacent subcutaneous fat
(such as that in the anterior axillary fold). Gynecomastia is felt
as symmetric, firm glandular tissue under the nipple. Testic-
ular examination was performed by palpation of both testes
and measurement of their volume by Prader orchidometer.
Given the low rate of testicular tumors that may be associated
with gynecomastia, palpation was performed in all patients,
while testicular ultrasound was not performed as routine, but
only requested when warranted by palpation findings or in
cases of hyperestrogenism of unknown etiology.
Routine and hormonal laboratory data were analyzed:
blood glucose, lipid profile, liver function tests, creatinine,
blood count, TT, E2, LH, FSH, PRL, and TSH. Oncologic
markers had also been ordered in most patients: alpha-
fetoprotein, 𝛽-subunit of human chorionic gonadotropin,
and carcinoembryonic antigen.
Hormonalmeasurements were performed using the assay
available at the site where the patient was seen (see Sup-
plementary Information (available here)). Blood samples
were taken at 8:00 am after 12-hour nocturnal fasting. For
biochemical abnormalities, reference values of each site were
considered.
Hypogonadism was defined by TT levels <3.0 ng/mL,
confirmed by repeat TT measurement [24], hyperprolactine-
mia by PRL levels >20 ng/mL, and hyperestrogenism by E2
levels >60 pg/mL.
Regarding age we divided the population into older and
younger than 40 years because (1) in longitudinal studies
it was shown that testosterone begins to gradually fall after
this age, (2) the median age of the population in this study
is closer to 40 years, and finally (3) the number of patients
between decades 41-50, 51-60, 61-70, 71-80, and >80 years is
more homogeneous than decades < 40 years.
2.1. Statistical Analysis. Data were analyzed using Instat
Statistical Software (GraphPad, version 3.01). Differences
in the characteristics between patients with unilateral or
bilateral gynecomastia were compared with a two-sample 𝑡-
test (parametric) or Mann–Whitney U test (not parametric)
for continuous variables. Data are presented as themean± SD
or median and range as appropriate. All 𝑝 values quoted are
two-sided, and values below0.05were regarded as statistically
significant.
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Table 1: Causes of gynecomastia in 237 patients (n = 244).
Causes N % TT (ng/mL) Prolactin (ng/mL) TSH (uIU/mL) LH (mIU/mL) FSH (mIU/mL) E2 (pg/mL)
Anabolic steroids 34 13.9 5.6 ± 1.3 13.7 ± 8.5 1.9 ± 0.8 4.0 ± 2.9 3.6 ± 1.9 30.3 ± 14.7
Hypogonadism 27 11.0 2.1 ± 1.1 13.9 ± 9.3 2.4 ± 0.6 19.2 ± 14.3 31.0 ± 23.2 29.9 ± 16.3
Pharmaceutical drugs 19 7.8 4.8 ± 2.0 24.1 ± 34.1 1.9 ± 0.8 11.5 ± 12.5 17.1 ± 21.3 35.9 ± 14.7
Persistent puberty 15 6.2 4.8 ± 2.0 13.7 ± 5.7 1.7 ± 1.0 4.8 ± 2.4 4.6 ± 4.3 30.1 ± 10.8
Hyperprolactinemia 14 5.7 4.2 ± 1.9 167.4 ± 335.9 2.8 ± 1.9 6.0 ± 6.2 12.0 ± 19.5 23.1 ± 9.7
Marijuana 8 3.3 8.3 ± 2.7 9.8 ± 3.1 2.5 ± 1.6 4.9 ± 1.6 3.3 ± 2.1 44.0 ± 20.3
Renal Failure 5 2.1 4.2 ± 2.3 16.7 ± 10.6 2.2 ± 1.4 8.9 ± 6.9 13.3 ± 14.9 24.2 ± 7.3
Hyperthyroidism 5 2.1 5.7 ± 2.6 11.0 ± 6.7 0.02 ± 0.02 4.0 ± 2.0 3.7 ± 1.8 36.0 ± 19.0
Chronic liver disease 3 1.2 4.5 ± 2.1 11.2 ± 4.4 1.9 ± 0.3 4.3 ± 0.6 5.6 ± 1.6 44.0 ± 30.8
Dietary phytosteroids 1 0.4 7.6 8.5 0.86 2.4 1.2 48
Hyperestrogenism 1 0.4 4.5 20 2.5 3.6 4 114
Refeeding 1 0.4 12.7 10.4 4.7 4.1 0.9 58
Adrenal carcinoma 1 0.4 2.4 78.1
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Figure 1: Age distribution of patients presenting with gynecomastia
(n = 237).
3. Results
The medical records of 435 males with a diagnosis of
gynecomastia were reviewed and 237 of these recordsmet the
inclusion criteria. The enrollment was performed as follows:
Department of Endocrinology, Metabolism and Nuclear
Medicine, Hospital Italiano n = 145; Endocrinology Division,
Hospital Durand n = 44; Department of Endocrinology and
Metabolism, Unidad Asistencial “Dr. Ce´sar Milstein” n = 18;
Department of Endocrinology, CentroMe´dico Haedo n = 17;
Department of Endocrinology, Complejo Me´dico Churruca-
Visca n = 9; Department of Endocrinology, Hospital Ramos
Mej´ıa n = 4.
Diagnosis was documented only by ultrasound in 56.2%
of patients, only by mammography in 16.4% of patients and
by both in 27.4% of patients.
The median age at the time of the first visit was 32 years
(range: 18 to 85 years). Figure 1 shows the age distribution of
patients.
Most patients presented spontaneously at the endocrinol-
ogy office (72.5%); the rest were referred by other specialists.
Main complaints included esthetic concerns in 62.8% of
patients and pain in 51.2% (20.2% for both complaints).
Gynecomastia was incidentally found on physical examina-
tion in 3.9% of patients seeking medical attention for other
reasons.
At the clinical interview, 25.3% of the study subjects
reported a history of pubertal gynecomastia. The duration of
disease before seeking specialized endocrine care was highly
variable, ranging from 1 month to 40 years (median: 1 year).
On physical examination, 134 patients (56.5%) had bilat-
eral and 103 (43.5%) unilateral gynecomastia (left in 54.4%
and right in 45.6%). The 39.9% of the study subjects were
overweight and 22.8% had obesity. The mean BMI was
27.0 ± 4.5 kg/m2. In 28.7% of patients, breast pain was
found on physical examination. One patient (with macro-
prolactinoma) reported spontaneous nipple discharge and in
3 patients, nipple discharge was found on physical exam-
ination. Of 156 with gonadal examination description, 126
(80.8%) had normal gonadal volume, 19 (12.2%) had bilateral
hypotrophy, 7 (4.5%) had unilateral hypotrophy, and 4 (2.5%)
had unilateral absence of the testicle (2 with hypotrophic
single testicle and 2 with trophic single testicle). Absence
of the testicle was confirmed by testicular ultrasound and
abdominal MRI in all cases.
As regards the analysis of etiologies, 134 causes were iden-
tified in 127 patients; in 7 cases 2 causes coexisted (Table 1).
Among the causes that were identified, consumption of
anabolic steroids was the most common (13.9%). Hypogo-
nadism was found in 11.1% of patients, hyperprolactinemia
in 5.7%, and hyperestrogenism in 0.4%. Of 27 patients with
hypogonadism, 20 were hypergonadotropic (9 patients with
Klinefelter’s Syndrome) and 7were hyponormogonadotropic.
Of the 14 patients with hyperprolactinemia, 6 had prolacti-
noma, and all others were considered to have idiopathic
hyperprolactinemia. Drug-induced hyperprolactinemia was
included within pharmacological causes. The drugs involved
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Table 2: Causes of gynecomastia and hormonal profiles in 160 patients 18-40 years old (n = 165).
Causes n % TT (ng/mL) Prolactin (ng/mL) TSH (uIU/mL) LH (mIU/mL) FSH (mIU/mL) E2 (pg/mL)
Anabolic steroids 32 19.4 5.7 ± 1.4 13.9 ± 8.7 1.9 ± 0.8 4.1 ± 3.0 3.5 ± 1.8 30.7 ± 15.0
Persistent puberty 14 8.5 5.0 ± 2.0 14.5 ± 5.1 1.8 ± 1.0 5.1 ± 2.3 4.6 ± 4.4 30.8 ± 10.9
Hyperprolactinemia 11 6.7 5.1 ± 2.0 185.4 ± 375.4 2.9 ± 2.3 7.4 ± 9.9 8.6 ± 13.9 29.8 ± 9.0
Hypogonadism 11 6.7 1.7 ± 1.9 13.0 ± 7.7 2.2 ± 0.4 19.0 ± 14.0 36.4 ± 24.8 30.3 ± 23.1
Marijuana 8 4.8 8.3 ± 2.7 9.8 ± 3.1 2.5 ± 1.6 4.9 ± 1.6 3.3 ± 2.1 44.0 ± 20.3
Pharmaceutical drugs 4 2.4 6.0 ± 0.8 13.9 ± 2.7 2.5 ± 1.0 5.2 ± 2.5 3.2 ± 2.5 31.7 ± 22.8
Hyperthyroidism 3 1.8 5.7 ± 2.6 11.0 ± 6.7 0.02 ± 0.02 4.0 ± 2.0 3.7 ± 1.8 36.0 ± 19.0
Renal failure 2 1.2 5.4 ± 0.8 16.5 ± 14.8 1.4 ± 0.3 5.9 ± 0.5 2.3 ± 0.1 18.5 ± 2.1
Dietary phytosteroids 1 0.6 7.6 8.5 0.86 2.4 1.2 48
Hyperestrogenism 1 0.6 4.5 20 2.5 3.6 4 114
Refeeding 1 0.6 12.7 10.4 4.7 4.1 0.9 58
Chronic liver disease 1 0.6 4.9 8.7 1.9 3.7 4.2 18
Idiopathic 76 46.1 5.7 ± 1.8 12.5 ± 4.6 2.1 ± 1.1 3.9 ± 2.0 3.5 ± 2.2 29.2 ± 9.4
Table 3: Causes of gynecomastia and hormonal profiles in 77 patients older than 40 years old (n = 79).
Causes n % TT (ng/mL) Prolactin (ng/mL) TSH (uIU/mL) LH (mIU/mL) FSH (mIU/mL) E2 (pg/mL)
Hypogonadism 16 20.3 2.3 ± 0.7 14.4 ± 10.4 2.4 ± 0.7 18.0 ± 15.2 27.4 ± 22.2 33.1 ± 16.4
Pharmaceutical drugs 15 19.0 4.5 ± 2.1 26.2 ± 37.4 1.7 ± 0.8 13.0 ± 13.5 20.6 ± 22.6 36.8 ± 13.5
Renal failure 3 3.8 3.4 ± 2.8 16.8 ± 10.7 2.5 ± 1.6 10.7 ± 9.0 17.0 ± 15.8 28.0 ± 7.0
Hyperprolactinemia 3 3.8 2.9 ± 0.6 104.8 ± 131.2 2.1 ± 0.6 4.9 ± 5.4 17.2 ± 26.6 15.5 ± 13.1
Liver chronic disease 2 2.5 4.9 ± 2.2 12.5 ± 5.4 1.6 ± 0.5 4.6 ± 0.4 6.3 ± 1.5 57.0 ± 29.7
Hyperthyroidism 2 2.5 3.3 ± 0.2 6.5 ± 2.1 0.01 ± 0.01 10.2 ± 1.7 7.9 ± 1.2 27.0 ± 2.8
Anabolic steroids 2 2.5 3.8 ± 0.1 8.8 ± 1.1 1.8 ± 0.2 4.2 ± 3.3 6.0 ± 0.9 29.1 ± 4.2
Adrenal carcinoma 1 1.3 2.4 78.1
Persistent puberty 1 1.3 2.3 2.8 0.9 1.2 3.8 20
Idiopathic 34 43.0 4.3 ± 1.0 11.8 ± 5.4 2.1 ± 1.6 5.1 ± 2.8 9.9 ± 8.3 26.8 ± 8.0
were finasteride (5 cases), antiretrovirals (4), spironolactone
(4), bicalutamide (1), dutasteride (1), pimozide (1), sulpiride
(1), flutamide (1), and LH-RH analog (1). No elevated tumor
markers were found in any of the cases. In 110 cases (45.1%),
it was not possible to establish an etiology and gynecomastia
was classified as idiopathic.
An analysis of etiologies according to age was performed.
The etiologies and hormonal values in <40 and >40 years are
described in Tables 2 and 3, respectively.
A certain etiology was more frequently identified in
young adults: anabolic consumption in patients with a mean
(± SD) age of 30.3 ± 7.2 years, persistent puberty: 24.4 ± 10.0
years, hyperprolactinemia: 34.9 ± 14.1 years, and marijuana
consumption: 27.3 ± 8.0 years. Conversely, gynecomastia
secondary to pharmacological drugs use was more frequent
in the elderly: 84.2% were older than 40 years, with a mean
age of 62.5 ± 20.6 years. The mean age of consultation for
gynecomastia in patients with hypogonadism was 48.6 ±
23.1 years, yet the subgroup of patients with Klinefelter’s
Syndrome (KS) were younger: 23.9 ± 6.9 years old.
Patients with bilateral gynecomastia had a longer time of
evolution as compared to those with unilateral disease: 3.4 ±
5.6 versus 1.4 ± 1.9 years (p = 0.0001); higher BMI: 27.8 ± 4.7
versus 25.7 ± 4.0 kg/m2 (p = 0.005); and lower TT levels: 4.6
± 2.1 versus 5.3 ± 2.0 ng/mL (p = 0.008), respectively.
4. Discussion
In this series of patients presenting with gynecomastia,
etiologies of gynecomastia were found in 54.9% of cases.
Among the causes detected, the use of anabolic steroids and
persistent pubertal gynecomastia were the most common in
the young population, while hypogonadism and the use of
drugs were the most common in elderly patients. The most
common complaints were esthetic concerns and breast pain.
Detection of galactorrhea was rare, gonadal examination
was normal in most patients, and 62.7% were overweight or
obese. As regards clinical presentation, our data show that
unilateral gynecomastia (there were no differences between
right and left occurrences) is almost as frequent as bilateral
gynecomastia. Anyway, it is important to remember that,
from a pathologic point of view, there is usually bilateral
involvement [23–25]. Slightly over half of patients presented
with bilateral gynecomastia, and when compared with cases
of unilateral gynecomastia these patients demonstrated a
longer duration of disease, higher BMI, and lower TT levels.
Gynecomastia is a common entity that may be brought
to the attention of the physician by the patient himself
or it may be found on a clinical examination performed
for other health problems. This difference in the way it is
detected (incidental finding or main complaint) determines
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and places a bias on the forms of presentation and the
various etiologies reported by different published case series
[26, 27]. Furthermore, the different methods of assessment
at each site certainly determine the higher or lower reported
frequency of idiopathic gynecomastia and of each probable
etiology.
Our analysis, though retrospective, included only cases
studied by a complete clinical, biochemical, and imaging
assessment, as suggested by various authors [2, 8, 16, 17].
Almost all patients presented directly for evaluation of
gynecomastia and in only 3.9% of the cases included in this
series this condition was discovered in patients who pre-
sented with other complaints. The fact that 72.5% of patients
initially sought advice from an endocrinologist is likely to be
biased by our own methodology, as only cases with complete
diagnostic assessments were eligible for inclusion and such
requirement is more likely to be met in the endocrinology
setting than in other specialties.
As gynecomastia is a chronic—often asymptomatic—
process, patients do not immediately seek medical attention.
In these cases, patients are referred to the specialist long after
the onset of signs and symptoms. Instead, in cases with a
recent onset of symptoms, which may be pain or discomfort,
medical attention is sought in the short term.The duration of
gynecomastia at the time of seeking medical attention in our
population was highly variable, ranging from 1 month to 40
years.
One-fourth of the patients had a history of pubertal
gynecomastia but in only 6.2% of cases persistence of this
condition was themain complaint.The frequency of pubertal
gynecomastia reported in different studies is higher than that
reported as history in our population [15, 21, 28]. Probably,
the prevalence of the history of pubertal gynecomastia in our
study was not higher because it was not as clinically relevant
as to be reported by patients. Furthermore, our criterion
of including only patients older than 18 also creates a bias
regarding the prevalence of this type of gynecomastia.
Patients with bilateral gynecomastia had longer dura-
tion of the condition, higher BMI, and lower TT levels
than patients with unilateral gynecomastia. No differences
occurred in plasma E2 levels between unilateral and bilateral
conditions, as it did occur in TT levels. It could be assumed,
in relation to pathophysiology, that patients with bilateral
presence of breast tissue have higher E2 levels locally, though
not peripherally, or that the longer duration of the condition
permitted chronic stimulation, which resulted in the bilateral
enlargement. Another possibility would be that patients with
lower testosterone levels might have a greater magnitude of
gynecomastia because of the lower inhibitory effect of this
hormone on breast tissue.
The proportion of patients with overweight and obesity
in our population was slightly higher than that reported in
a study conducted in an Argentine population of men aged
between 35 and 64 years (39.9% and 22.8% versus 34.8% and
14.8%, respectively) [29]. These observations would support
the concept of obesity as predisposing or “etiologic” factor;
however, we are aware that a larger sample is required to draw
conclusions about the specific influence of overweight and
obesity on gynecomastia.
As reported in other series, idiopathic gynecomastia was
the most common finding (45.1% of cases), although in our
study the percentage was lower than that reported in other
studies (58-61%) [27, 30–32]. The fact that all patients were
evaluated in endocrinology departments and that biochemi-
cal and imaging tests were part of the inclusion criteria may
account for the identification of more causes. Nevertheless,
we have to mention also that almost 50% (45.5%) of the men
initially identified were excluded, which shows that half of
the patients with gynecomastia are not completely studied,
at least in our institutions.
Among the causes identified, the most prevalent was the
use of anabolic steroids (13.9%). The rate of occurrence of
the various etiologies is related to the age of the population:
use of anabolic steroids in younger patients and use of
pharmaceutical drugs and hypogonadism in older ones.
When dividing the population into older and younger than
40 years, as shown in Tables 2 and 3, the rate of occurrence of
the various etiologies changes, with no significant variation
in the rate of the idiopathic etiology. Among detectable
causes in subjects younger than 40 years, the most prevalent
were the use of anabolic steroids, persistent pubertal gyneco-
mastia, hyperprolactinemia, hypogonadism and the use of
marijuana. These five causes constitute 89.3% of identifiable
causes in this group. In the group of men older than 40 years,
hypogonadism and the use of pharmaceutical drugs were
the most common causes, accounting for 72.1% of secondary
causes in this age group.
Despite the low frequency of etiologies such as thy-
roid dysfunction or adrenal carcinoma, we emphasize the
importance of a thorough assessment of the patient, as
gynecomastia may be the tip of the iceberg for the diag-
nosis of potentially treatable diseases. In nine cases (3.8%),
gynecomastia was associated with KS. The prevalence of KS
in this series is relatively low because only those cases in
which gynecomastia was the main complaint were included.
In a previous study where 54 patients with KS older than 18
years were evaluated, we found a prevalence of gynecomastia
of 31.3% [33]. Furthermore, patients with KS are likely to
seek medical attention for gynecomastia before the age of
18 (at a younger age than that of our study population).
In addition to the KS cases, 11 patients had hypogonadism
with elevated gonadotropin levels. All of them had normal
karyotype and/or testicular volume inconsistent with KS.
The etiology of gynecomastia has been evaluated in a
reduced number of published series. In 53 young patients, the
etiology was found to be idiopathic in 58% of cases, while
secondary causes included hypogonadism (25%), hyper-
prolactinemia (9%), chronic liver disease (4%), and drug-
induced disease (4%) [31]. In another retrospective study of
87 patients, idiopathic gynecomastia was detected in 61% of
patients, while this disease was induced by drugs in 21%, by
liver or kidney disease in 16% and hyperthyroidism in 2%
[27]. Mieritz et al. found 57% of “unexplained gynecomastia”
and 15.2% of patients had testosterone deficiency [32].
All patients had imaging studies (ultrasound and/or
mammography) as this was an inclusion criterion. Both
ultrasound and mammography may also help to differentiate
between lipomastia and gynecomastia if doubts arise during
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physical examination. Mammography is the study of choice
when breast cancer is suspected, as it has a negative predictive
value above 90%, and over 90% sensitivity and specificity for
differentiating between benign and malignant disease in the
breast [27]. Testicular ultrasound was ordered when abnor-
mal findings were detected on palpation of the testes or in
cases of hyperestrogenism of unknown etiology. No testicular
pathology was detected on ultrasound when performed.
In conclusion, the analysis of these results suggests that
although there are a large proportion of idiopathic cases,
gynecomastia may be the expression of a relevant underlying
clinical condition. This highlights the need for an adequate
and complete clinical, biochemical, and imaging assessment
of these patients.
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 Supplementary Information 
 
Methods used for hormone determinations: hormone levels were measured using the 
assay available at each of the participating sites, as described below: 
 
- Total Testosterone (TT) was measured using: 
1) Chemiluminescence on the Immulite 2000 (Siemens) analyzer, laboratory reference 
ranges: 3.0-8.8 ng/mL for adult males; the intra-assay coefficient of variation was 7.5% 
and the inter-assay coefficient of variation was 8.1% (n=145).  
2) Chemiluminescence immunoassay on the Access Beckman Coulter analyzer, 
laboratory reference ranges: 3.0-9.0 ng/mL for adult males; the intra-assay coefficient 
variation was 10.0% and the inter-assay coefficient of variation was 8.5% (n=48). 
3) Chemiluminescence immunoassay on the Cobas e411 (Roche) analyzer, laboratory 
reference ranges: 3.0-9.0 ng/ml for adult males; the intra-assay coefficient of variation 
was 1.8% and the inter-assay coefficient of variation was 7.7% (n=44) 
- Prolactin was measured using: 
1) Chemiluminescence immunoassay on the Architect (Abbott) analyzer, the lower limit 
of detection was 0.6 ng/mL, laboratory reference ranges: 5-20 ng/mL; the intra-assay 
coefficient of variation was 4.7% and the inter-assay coefficient of variation was 5.9% 
(n=145). 
2) Chemiluminescence immunoassay Liasion Día Sorin, laboratory reference ranges: 2-
14 ng/mL; the intra-assay coefficient of variation was 3.2% and the inter-assay 
coefficient of variation was 3.0% (n=48). 
 3) Chemiluminescence immunoassay on the ADVIA Centaur XP (Siemens) analyzer, 
laboratory reference ranges: 2-18 ng/mL; the intra-assay coefficient of variation was 
2.8% and the inter-assay coefficient of variation was 6.3% (n=44). 
- TSH was measured using: 
1) Chemiluminescence immunoassay on the Architect (Abbott) analyzer, laboratory 
reference ranges: 0.47-4.64 ng/mL; the intra-assay coefficient of variation was 2.6% and 
the inter-assay coefficient of variation was 4.2% (n=145). 
2) Chemiluminescence immunoassay on the Access Beckman Coulter analyzer, 
laboratory reference ranges: 0.5-4.5 uIU/mL; the intra-assay coefficient of variation was 
5.6% and the inter-assay coefficient of variation was 3.02% (n=48).  
3) Chemiluminescence immunoassay on the ADVIA Centaur XP (Siemens) analyzer, 
laboratory reference ranges: 0.35-4.5 mIU/L; the intra-assay coefficient of variation was 
2.85% and the inter-assay coefficient of variation was 5.3% (n=44). 
- LH was measured using: 
1) Chemiluminescence immunoassay on the Architect (Abbott) analyzer, laboratory 
reference ranges: 2-12 mIU/mL; the intra-assay coefficient of variation was 4.1% and 
the inter-assay coefficient of variation was 4.3% (n=145). 
2) Chemiluminescence immunoassay on the Access Beckman Coulter analyzer, 
laboratory reference ranges: 1.7-8.6 mIU/mL; the intra-assay coefficient of variation 
was 4.06% and the inter-assay coefficient of variation was 3.7% (n=48).  
 3) Chemiluminescence immunoassay on the ADVIA Centaur XP (Siemens) analyzer, 
laboratory reference ranges: 1.5-9.2 mIU/mL; the intra-assay coefficient of variation 
was 3.0% and the inter-assay coefficient of variation was 7.2% (n=44). 
- FSH was measured using: 
1) Chemiluminescence immunoassay on the Architect (Abbott) analyzer, laboratory 
reference ranges: 1-8 mIU/mL; the intra-assay coefficient of variation was 4.6% and the 
inter-assay coefficient of variation was 4.3% (n=145). 
2) Chemiluminescence immunoassay on the Access Beckman Coulter analyzer, 
laboratory reference ranges: 1.5-12.4 mIU/mL; the intra-assay coefficient of variation 
was 4.06% and the inter-assay coefficient of variation was 3.7% (n=48).  
3) Chemiluminescence immunoassay on the ADVIA Centaur XP (Siemens) analyzer, 
laboratory reference ranges: 1.0-14.0 mIU/mL; the intra-assay coefficient of variation 
was 2.9% and the inter-assay coefficient of variation was 6.2% (n=44). 
- E2 was measured using: 
1) Chemiluminescence immunoassay on the Architect (Abbott) analyzer, laboratory 
reference ranges: 18-44 pg/mL; the intra-assay coefficient of variation was 7.4% and the 
inter-assay coefficient of variation was 4.5% (n=145). 
2) Chemiluminescence immunoassay on the Access Beckman Coulter analyzer, 
laboratory reference ranges: 10-60 pg/mL; the intra-assay coefficient of variation was 
20% and the inter-assay coefficient of variation was 15% (n=48).  
 3) Electrochemiluminescence on the Cobas e411 (Roche) analyzer, laboratory reference 
ranges: 25-60 pg/mL; the intra-assay coefficient of variation was 3.5% and the inter-
assay coefficient of variation was 7.7% (n=44). 
 
 
